Drug intelligence / Profile preview

E-islet 01

Development stage: Phase 2
Lead developer: EndoCell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

E-islet 01 is an investigational, stem-cell-derived pancreatic islet cell therapy developed by Eli Lilly for the treatment of Type 1 Diabetes (T1D). The therapy consists of insulin-producing cells derived from a proprietary stem cell line, designed to replace the endogenous beta cells destroyed by the autoimmune process in T1D patients. By restoring the body's ability to produce insulin in response to glucose levels, E-islet 01 aims to improve glycemic control, eliminate severe hypoglycemic events, and restore hypoglycemic awareness. The cells are typically administered via infusion into the hepatic portal vein, where they engraft in the liver and function as an auxiliary endocrine organ.

Other names: Stem-cell derived islet cell therapy

Beyond the preview

Go deeper on E-islet 01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E-islet 01.

Explore the full profile